Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$1.78
-$0.20(-3.17%)
At close: 4:00 PM EST
$1.78
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.15 - $3.56
Previous CloseN/A
Volume1.72K
Average Volume (3M)996.44K
Market Cap
$76.19M
Enterprise Value$16.32M
Total Cash (Recent Filing)$97.74M
Total Debt (Recent Filing)$2.42M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,801,727
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit71.56
Enterprise Value/Ebitda-0.20
Forecast
1Y Price Target
$11.33Price Target Upside536.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.50M
Bulls Say, Bears Say
Bulls Say
Proprietary Precision Platform (AP3)Acrivon's AP3 proteomics platform is a durable competitive asset: biomarker-driven patient selection can raise trial success odds, enable targeted registrational strategies, and support companion diagnostics or partnerships, improving long-term development efficiency and differentiation.
Strong Clinical Signal For ACR-368A substantial 52% ORR in a registrational-intent Phase 2b serous cohort materially de-risks the lead program: sustained efficacy in a high-unmet-need indication supports a clearer regulatory path, strengthens commercialization potential, and validates the science for longer-term value creation.
Near-term Cash RunwayAcrcivon’s cash runway into Q2 2027 provides a structural buffer to advance registrational trials, launch the CLIA lab, and progress discovery programs without immediate financing. This reduces short-term funding pressure and gives time to achieve value-creating clinical milestones.
Bears Say
Pre-revenue With Persistent Cash BurnAs a pre-revenue biotech, Acrivon records persistent negative operating and free cash flow, forcing reliance on external funding. Over 2-6 months this structural cash burn compresses runway if milestones slip and increases financing frequency and dilution risk for shareholders.
Eroding Equity / Negative Returns On EquityA marked decline in shareholders' equity reflects accumulated losses and capital consumed by development. Persistent negative ROE signals the business currently cannot generate shareholder returns, weakening the balance-sheet resilience and long-term financial flexibility.
Institutionalized Dilution RiskThe expanded incentive plan and automatic annual share increases institutionalize future equity issuance, raising the likelihood of long-term share count growth. This structural dilution can impair per-share economics and investor returns as development requires further funding or equity-based compensation.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.15 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $76.19M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 49 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.035.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.5.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 42,801,727 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.33 (536.70% Upside)
$11.33 (536.70% Upside)
Hedge Fund Trend
Decreased
By 22.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
-64.43%
Trailing 12-Months
Asset Growth
-38.85%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$11.33
▲(536.70% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
35.82% Insiders
2.57% Mutual Funds
25.02% Other Institutional Investors
34.67% Public Companies and Individual Investors
Options Prices
Currently, No data available
---